HC Wainwright Estimates Alumis' Q3 Earnings (NASDAQ:ALMS)

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share (EPS) estimate for Alumis Inc. from ($0.74) to ($0.80), while maintaining a "Buy" rating and a price target of $14.00.
• Alumis reported a loss of ($1.17) EPS for the last quarter, missing the consensus estimate, but achieved revenues of $2.67 million, exceeding analyst expectations.
• Consensus estimates for Alumis' full-year earnings indicate a significant loss of ($8.51) per share, with various analysts providing differing price targets ranging from $17.00 to $25.00.

Alumis Inc. (NASDAQ:ALMS - Free Report) - HC Wainwright decreased their Q3 2025 EPS estimates for shares of Alumis in a report issued on Thursday, August 14th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.80) per share for the quarter, down from their prior estimate of ($0.74). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis' Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($4.34) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.49) EPS.

ALMS has been the subject of several other reports. Wall Street Zen raised shares of Alumis from a "strong sell" rating to a "hold" rating in a report on Saturday, August 16th. Morgan Stanley reduced their target price on shares of Alumis from $23.00 to $22.00 and set an "overweight" rating for the company in a report on Friday, August 15th. Wells Fargo & Company started coverage on shares of Alumis in a research report on Friday, July 25th. They issued an "overweight" rating and a $17.00 price target for the company. Guggenheim upgraded shares of Alumis to a "buy" rating and set a $18.00 price target for the company in a research report on Tuesday, June 10th. Finally, Oppenheimer dropped their price target on shares of Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat, Alumis currently has an average rating of "Buy" and an average price target of $20.17.

Alumis Trading Up 3.5%

Shares of ALMS traded up $0.1550 during trading hours on Monday, reaching $4.5650. 286,738 shares of the company traded hands, compared to its average volume of 704,233. Alumis has a 12 month low of $2.76 and a 12 month high of $13.11. The company's fifty day moving average price is $3.66 and its two-hundred day moving average price is $4.63.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.06). The firm had revenue of $2.67 million for the quarter, compared to analysts' expectations of $1.80 million.

Hedge Funds Weigh In On Alumis

Several large investors have recently made changes to their positions in the company. Marshall Wace LLP purchased a new position in Alumis during the fourth quarter worth about $108,000. Tang Capital Management LLC lifted its stake in Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company's stock worth $4,716,000 after acquiring an additional 173,406 shares during the last quarter. Foresite Capital Management V LLC lifted its stake in Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company's stock worth $45,426,000 after acquiring an additional 194,459 shares during the last quarter. Barclays PLC lifted its stake in Alumis by 33.9% in the fourth quarter. Barclays PLC now owns 24,581 shares of the company's stock worth $193,000 after acquiring an additional 6,221 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Alumis by 4.3% in the fourth quarter. Northern Trust Corp now owns 111,326 shares of the company's stock worth $875,000 after acquiring an additional 4,587 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.